2014 Discharge: Innovative Medicines Initiative 2 (IMI)

This procedure concerns the 'discharge' process, which is the final approval of how the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking managed its budget for the 2014 financial year. It ensures that public funds used for pharmaceutical research and development were spent legally, regularly, and efficiently.

This affects the management of the IMI2 Joint Undertaking and the public-private partnerships involved in developing new medicines and treatments across the EU.